PH27210A - Compounds having a cognition adjuvant action and the use thereof for the treatments and prophylaxis of cognitive dysfunction - Google Patents

Compounds having a cognition adjuvant action and the use thereof for the treatments and prophylaxis of cognitive dysfunction

Info

Publication number
PH27210A
PH27210A PH35073A PH35073A PH27210A PH 27210 A PH27210 A PH 27210A PH 35073 A PH35073 A PH 35073A PH 35073 A PH35073 A PH 35073A PH 27210 A PH27210 A PH 27210A
Authority
PH
Philippines
Prior art keywords
prophylaxis
compounds
treatments
cognitive dysfunction
adjuvant action
Prior art date
Application number
PH35073A
Inventor
Franz Hock
Hansjorg Urbach
Rainer Henning
Ulrich Lerch
Wolf-Ulrich Nickel
Wolfgang Ruger
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag filed Critical Hoechst Ag
Publication of PH27210A publication Critical patent/PH27210A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/022—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -X-C(=O)-(C)n-N-C-C(=O)-Y-; X and Y being heteroatoms; n being 1 or 2
    • C07K5/0222—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -X-C(=O)-(C)n-N-C-C(=O)-Y-; X and Y being heteroatoms; n being 1 or 2 with the first amino acid being heterocyclic, e.g. Pro, Trp
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Epoxy Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

The invention relates to novel compounds having a nootropic activity, the use of ACE inhibitors as medicaments having nootropic activity, agents containing them, and their use in the treatment and prophylaxis of cognitive malfunctions.
PH35073A 1986-03-27 1987-03-25 Compounds having a cognition adjuvant action and the use thereof for the treatments and prophylaxis of cognitive dysfunction PH27210A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19863610391 DE3610391A1 (en) 1986-03-27 1986-03-27 COMPOUNDS WITH NOOTROPPER ACTION, THESE CONTAINERS AND THEIR USE IN THE TREATMENT AND PROPHYLAXIS OF COGNITIVE DYSFUNCTIONS

Publications (1)

Publication Number Publication Date
PH27210A true PH27210A (en) 1993-05-04

Family

ID=6297417

Family Applications (1)

Application Number Title Priority Date Filing Date
PH35073A PH27210A (en) 1986-03-27 1987-03-25 Compounds having a cognition adjuvant action and the use thereof for the treatments and prophylaxis of cognitive dysfunction

Country Status (25)

Country Link
EP (1) EP0243645B1 (en)
JP (1) JPS62240698A (en)
KR (1) KR870008841A (en)
CN (1) CN1031267C (en)
AT (1) ATE102954T1 (en)
AU (1) AU621278B2 (en)
CA (1) CA1341064C (en)
CS (2) CS276179B6 (en)
DD (1) DD280765A5 (en)
DE (2) DE3610391A1 (en)
DK (1) DK172221B1 (en)
EG (1) EG18175A (en)
ES (1) ES2061447T3 (en)
FI (1) FI91876C (en)
HU (2) HU202118B (en)
IE (1) IE62456B1 (en)
MA (1) MA20919A1 (en)
NO (1) NO178546C (en)
NZ (1) NZ219764A (en)
OA (1) OA08506A (en)
PH (1) PH27210A (en)
PT (1) PT84564B (en)
RU (1) RU1836335C (en)
TN (1) TNSN87045A1 (en)
ZA (1) ZA872230B (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5231084A (en) * 1986-03-27 1993-07-27 Hoechst Aktiengesellschaft Compounds having a cognition adjuvant action, agents containing them, and the use thereof for the treatment and prophylaxis of cognitive dysfuncitons
US4743450A (en) * 1987-02-24 1988-05-10 Warner-Lambert Company Stabilized compositions
AU612137B2 (en) * 1987-04-27 1991-07-04 E.R. Squibb & Sons, Inc. Method for inhibiting loss of cognitive functions employing an ace inhibitor
DE3731085A1 (en) * 1987-09-16 1989-04-06 Hoechst Ag NEW AMINO ACID ESTERS, METHOD FOR THE PRODUCTION THEREOF, MEDICINAL PRODUCTS CONTAINING THEM AND THE USE THEREOF
DE3739690A1 (en) * 1987-11-24 1989-06-08 Hoechst Ag STABILIZED MEDICINAL PRODUCTS, METHOD FOR THEIR PRODUCTION AND STABLE MEDICAL PREPARATIONS
DE3801587A1 (en) * 1988-01-21 1989-08-03 Hoechst Ag NEW AMINO ACID GLYCERIDES, METHOD FOR THE PRODUCTION THEREOF, MEDICINAL PRODUCTS CONTAINING THEM AND THE USE THEREOF
EP0331609A3 (en) * 1988-01-27 1992-07-01 Hoechst Aktiengesellschaft Angiotensin converting enzyme inhibitors having psychotropic effects
DE3803225A1 (en) * 1988-02-04 1989-08-17 Hoechst Ag AMINO ACID AMIDE WITH PSYCHOTROPIC EFFECT, METHOD FOR THE PRODUCTION THEREOF, AGENTS CONTAINING THE SAME AND THEIR USE
JPH01275529A (en) * 1988-03-21 1989-11-06 E R Squibb & Sons Inc Suppressing treatment agent of delayed motion effect
US5037821A (en) * 1988-06-01 1991-08-06 E. R. Squibb & Sons, Inc. Method for inhibiting loss of cognitive functions employing a calcium channel blocker alone or in combination with an ACE inhibitor
US5093129A (en) * 1989-01-30 1992-03-03 E. R. Squibb & Sons, Inc. Method for treating addiction to a drug of abuse employing an ace inhibitor
US5032578A (en) * 1990-09-17 1991-07-16 E. R. Squibb & Sons, Inc. Method for preventing or treating depression employing a combination of an ace inhibitor and a drug that acts at serotonin receptors
EP1372620A2 (en) * 2001-03-15 2004-01-02 Saegis Pharmaceuticals Methods for restoring cognitive function following systemic stress

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0050800B2 (en) * 1980-10-23 1995-06-07 Schering Corporation Carboxyalkyl dipeptides, processes for their production and pharmaceutical compositions containing them
DE3300774A1 (en) * 1983-01-12 1984-07-12 Hoechst Ag, 6230 Frankfurt NEW SPIROCYCLIC AMINO ACIDS, METHOD FOR THE PRODUCTION THEREOF AND THE USE THEREOF AND NEW SPIROCYCLIC AMINO ACIDS AS INTERMEDIATE PRODUCTS AND METHOD FOR THE PRODUCTION THEREOF

Also Published As

Publication number Publication date
OA08506A (en) 1988-07-29
KR870008841A (en) 1987-10-21
CS276385B6 (en) 1992-05-13
IE62456B1 (en) 1995-02-08
ZA872230B (en) 1987-09-21
CA1341064C (en) 2000-08-01
MA20919A1 (en) 1987-10-01
ATE102954T1 (en) 1994-04-15
NO871282L (en) 1987-09-28
HUT46046A (en) 1988-09-28
AU621278B2 (en) 1992-03-12
FI871304A0 (en) 1987-03-25
DK172221B1 (en) 1998-01-12
EG18175A (en) 1994-07-30
HU203117B (en) 1991-05-28
PT84564A (en) 1987-04-01
IE870784L (en) 1987-09-27
DE3610391A1 (en) 1987-10-08
PT84564B (en) 1989-11-10
NZ219764A (en) 1990-11-27
FI871304A7 (en) 1987-09-28
NO178546B (en) 1996-01-08
TNSN87045A1 (en) 1990-01-01
CS212687A3 (en) 1992-04-15
NO871282D0 (en) 1987-03-26
JPS62240698A (en) 1987-10-21
DE3789330D1 (en) 1994-04-21
DK153587D0 (en) 1987-03-26
AU7064987A (en) 1987-10-01
EP0243645B1 (en) 1994-03-16
CS276179B6 (en) 1992-04-15
CN87102304A (en) 1987-12-30
CS651989A3 (en) 1992-05-13
FI91876C (en) 1994-08-25
DD280765A5 (en) 1990-07-18
FI91876B (en) 1994-05-13
NO178546C (en) 1996-04-17
HU896609D0 (en) 1990-02-28
RU1836335C (en) 1993-08-23
EP0243645A3 (en) 1990-01-24
ES2061447T3 (en) 1994-12-16
DK153587A (en) 1987-09-28
HU202118B (en) 1991-02-28
CN1031267C (en) 1996-03-13
EP0243645A2 (en) 1987-11-04

Similar Documents

Publication Publication Date Title
HU912359D0 (en) The use of flupirtine active agents for treating muscle-tension
ZA872230B (en) Compounds having a cognition adjuvant action,agents containing them,and the use thereof for the treatment and prophylaxis of cognitive dysfunctions
IL89031A0 (en) Medicaments containing a benzamide for the treatment or prevention of cognitive disorders and their preparation
OA09917A (en) Compounds for use in treating HIV infection
ZA886459B (en) Use of bezafibrate for treating diabetes
GB8823605D0 (en) Therapeutic agents
ZA877454B (en) Therapeutic agent for the treatment of peptic ulcer disease
IE872540L (en) Method of promoting wound-healing
EP0353910A3 (en) Human interferon-gamma, process for preparing said human interferon-gamma, and its use
EP0458537A3 (en) Therapeutic compound for the treatment of bronchitis
EP0182569A3 (en) Use of 1,6-dimethyl-4-oxo-1,6,7,8,9a-hexahydro-4h-pyridoû1,2-a¨pyrimidine-3-carboxamide for the prevention and treatment of gastrointestinal damages
JO1516B1 (en) Compounds having a congnition adjuvant action, agents containing them, and the use thereof for the treatment and prophylaxis of cognitive dysfunctions
MTP1001B (en) Compounds having a cognition adjuvant action,agents containing them,and the use of there of for treatment and prophylaxis of cognitive dysfunctions (hoe 86/f069)
HUT43492A (en) Process for preventing and healing of gastrointestinic damages by using 3-ethoxicarbonil--1,6-dimethil-4-oxo-6,7,8,9-tetrahydro-4-h-pirido-/1,2-a/-pirimidinium-metha sulphate
GR3006610T3 (en)
ZA89574B (en) Compounds with a psychotropic action,agents containing them,and the use thereof for the treatment and prophylaxis of disorders of the central nervous system